Loading...

Deanna Kroetz, PhD

TitleProfessor
SchoolUCSF School of Pharmacy
DepartmentBioengineering
Address1550 4th Street, Bldg 19B
San Francisco CA 94158
Phone415-476-1159
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    National Pharmaceutical Council 1984  - 1984National Pharmaceutical Council Internship Mortar Board Honor Society Rho Chi National Pharmacy Ho
    Cum Laude Graduate Ohio State University College of Pharmacy1985  - 1985Ohio State University Presidential Scholar Eli Lilly Company Achievement Award
    National Institute of Health Training1987  - 1990National Institute of Health Training Grant Trainee
    Pharmacology Research Associate Training1991  - 1993Pharmacology Research Associate Training (PRAT) Fellowship
    Ohio State University College of Pharmacy1995  - 1995Josephine S. Failer Alumni Award
    American Association of Pharmaceutical Scientists 1996  - 1996American Association of Pharmaceutical Scientists Young Investigator Award in Pharmacokinetics, Phar
    American Society for Clinical Pharmacology and Therapeutics2002  - 2002Leon I. Goldberg Young Investigator Award
    American Heart Association2002  - 2002Elected Fellow, High Blood Pressure Research Council of the American Heart Association
    American Association of Pharmaceutical Scientists2008  - 2008Elected Fellow, American Association of Pharmaceutical Scientists
    Pharmacology2008  - 2008Named to Faculty of 1000, Pharmacology

    Collapse Overview 
    Collapse Overview
    The Kroetz lab has two major research areas. A major goal is to understand the role of genetic variation in determining drug response and toxicity. Integrated genomic and functional studies are focused on identifying genetic biomarkers of taxane-induced sensory peripheral neuropathy and response to antiretroviral therapies. A second area of research is on the role of cytochrome P450 eicosanoids in acute and chronic renal dysfunction. Animal and cellular studies are used to test whether inhibition of soluble epoxide hydrolase can be targeted for renoprotection.


    Collapse Research 
    Collapse Research Activities and Funding
    Pharmacogenomics of Microtubule Targeting Agents
    NIH/NCI R01CA192156Jul 2, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Mechanisms of Renoprotection by Soluble Epoxide Hydrolase Inhibition
    NIH/NIDDK R01DK084147Aug 1, 2010 - Jul 31, 2015
    Role: Principal Investigator
    CYTOCHROME P450 DEPENDENT ARACHIDONIC ACID METABOLISM
    NIH/NHLBI R01HL053994Aug 1, 1996 - Jul 31, 2006
    Role: Principal Investigator
    PHARMACOLOGICAL EFFECTS OF CYTOCHROME P450 4A METABOLISM
    NIH/NHLBI R29HL053994Aug 1, 1996 - Jul 31, 2000
    Role: Principal Investigator
    Pharmaceutical Sciences and Pharmacogenomics
    NIH/NIGMS T32GM007175Jul 1, 1982 - Jun 30, 2022
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Featured Videos
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Eclov RJ, Kim MJ, Chhibber A, Smith RP, Ahituv N, Kroetz D. ABCG2 regulatory single-nucleotide polymorphisms alter in-vivo enhancer activity and expression. Pharmacogenet Genomics. 2017 Sep 18. PMID: 28930109.
      View in: PubMed
    2. Li M, Kroetz D. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2017 Sep 04. PMID: 28882537.
      View in: PubMed
    3. Stage TB, Bergmann TK, Kroetz D. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. Clin Pharmacokinet. 2017 Jun 13. PMID: 28612269.
      View in: PubMed
    4. Chua KC, Kroetz D. Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy. Clin Pharmacol Ther. 2017 Apr; 101(4):450-452. PMID: 27981569.
      View in: PubMed
    5. Eclov RJ, Kim MJ, Smith RP, Liang X, Ahituv N, Kroetz D. In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. Drug Metab Dispos. 2017 Feb; 45(2):208-215. PMID: 27856528.
      View in: PubMed
    6. Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz D. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2016 Nov 15. PMID: 27845419.
      View in: PubMed
    7. Yee SW, Giacomini MM, Hsueh CH, Weitz D, Liang X, Goswami S, Kinchen JM, Coelho A, Zur AA, Mertsch K, Brian W, Kroetz D, Giacomini KM, et al. Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1. Clin Pharmacol Ther. 2016 Nov; 100(5):524-536. PMID: 27447836.
      View in: PubMed
    8. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz D, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. PMID: 27143689.
      View in: PubMed
    9. Chhibber A, French CE, Yee SW, Gamazon ER, Theusch E, Qin X, Webb A, Papp AC, Wang A, Simmons CQ, Konkashbaev A, Chaudhry AS, Mitchel K, Stryke D, Ferrin TE, Weiss ST, Kroetz D, Sadee W, Nickerson DA, Krauss RM, George AL, Schuetz EG, Medina MW, Cox NJ, Scherer SE, Giacomini KM, Brenner SE. Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines. Pharmacogenomics J. 2017 Mar; 17(2):137-145. PMID: 26856248.
      View in: PubMed
    10. Yuan B, Yoshino Y, Fukushima H, Markova S, Takagi N, Toyoda H, Kroetz D. Multidrug resistance-associated protein 4 is a determinant of arsenite resistance. Oncol Rep. 2016 Jan; 35(1):147-54. PMID: 26497925.
      View in: PubMed
    11. Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz D, Zhang W, Nakamura Y, Dolan ME. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46. PMID: 26015512; PMCID: PMC4592389 [Available on 10/01/16].
    12. Barbarino JM, Kroetz D, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics. 2015 Apr; 25(4):205-21. PMID: 25647431; PMCID: PMC4356642.
    13. Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz D. SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. Neurobiol Dis. 2015 May; 77:127-40. PMID: 25766675; PMCID: PMC4404495.
    14. Chhibber A, Kroetz D, Tantisira KG, McGeachie M, Cheng C, Plenge R, Stahl E, Sadee W, Ritchie MD, Pendergrass SA. Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics. 2014 Dec; 15(16):2025-48. PMID: 25521360; PMCID: PMC4308414.
    15. Barbarino JM, Kroetz D, Altman RB, Klein TE. PharmGKB summary: abacavir pathway. Pharmacogenet Genomics. 2014 May; 24(5):276-82. PMID: 24625462; PMCID: PMC4074515.
    16. Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz D. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014 May; 95(5):499-500. PMID: 24561393; PMCID: PMC3994233.
    17. Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz D. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 2014 Aug; 14(4):336-42. PMID: 24513692; PMCID: PMC4111770.
    18. Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz D, Kashuba AD. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol. 2014 May; 54(5):574-83. PMID: 24343710; PMCID: PMC4061289.
    19. Markova SM, Schwartz JB, Kroetz D. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers". Clin Pharmacol Ther. 2014 Mar; 95(3):252. PMID: 24346422.
      View in: PubMed
    20. Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz D. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics. 2013 Nov; 23(11):591-6. PMID: 23982262; PMCID: PMC4048019.
    21. Markova SM, Kroetz D. ABCC4 is regulated by microRNA-124a and microRNA-506. Biochem Pharmacol. 2014 Feb 01; 87(3):515-22. PMID: 24184504; PMCID: PMC3927324.
    22. Liu Y, Lu X, Nguyen S, Olson JL, Webb HK, Kroetz D. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol Pharmacol. 2013 Dec; 84(6):925-34. PMID: 24092818; PMCID: PMC3834146.
    23. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz D, Weinshilboum R, Cox NJ, Roden DM. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013 Aug; 23(8):383-94. PMID: 20639796; PMCID: PMC3003940.
    24. Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz D. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther. 2013 Dec; 94(6):678-86. PMID: 23863877; PMCID: PMC3834031.
    25. Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz D, Kwok PY. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics. 2013 Jul; 23(7):355-64. PMID: 23652407; PMCID: PMC3894639.
    26. Martin MA, Kroetz D. Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy. 2013 Jul; 33(7):765-75. PMID: 23649914; PMCID: PMC3700656.
    27. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz D, Egorin MJ, McLeod HL, Ratain MJ. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33. PMID: 23188068; PMCID: PMC3647228.
    28. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz D, Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9. PMID: 23204130; PMCID: PMC3549006.
    29. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz D, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8. PMID: 22851270.
      View in: PubMed
    30. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz D. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109. PMID: 22843789; PMCID: PMC3445665.
    31. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95. PMID: 22671777.
      View in: PubMed
    32. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz D. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J. 2013 Oct; 13(5):396-402. PMID: 22664480; PMCID: PMC3435480.
    33. Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz D. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor ?B signaling. J Pharmacol Exp Ther. 2012 Jun; 341(3):725-34. PMID: 22414856; PMCID: PMC3362876.
    34. Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM. Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. Cancer. 2012 Oct 15; 118(20):5060-8. PMID: 22415847.
      View in: PubMed
    35. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz D. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012 Apr; 91(4):734-8. PMID: 22378157; PMCID: PMC3374459.
    36. Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz D, Toyoda H. Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol. 2011 Dec 01; 257(2):198-208. PMID: 21945491; PMCID: PMC3470788.
    37. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz D, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May; 21(5):280-8. PMID: 21386754; PMCID: PMC3076530.
    38. Matsson P, Yee SW, Markova S, Morrissey K, Jenkins G, Xuan J, Jorgenson E, Kroetz D, Giacomini KM. Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. Pharmacogenomics J. 2012 Jun; 12(3):214-26. PMID: 21383772; PMCID: PMC3325368.
    39. Kim MJ, Skewes-Cox P, Fukushima H, Hesselson S, Yee SW, Ramsey LB, Nguyen L, Eshragh JL, Castro RA, Wen CC, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Relling MV, Giacomini KM, Kroetz D, Ahituv N. Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther. 2011 Apr; 89(4):571-8. PMID: 21368754; PMCID: PMC3227682.
    40. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz D, Klein TE, Altman RB. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011 Mar; 21(3):152-61. PMID: 20216335; PMCID: PMC3098758.
    41. Hoppe R, Brauch H, Kroetz D, Esteller M. Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine. Genome Biol. 2011; 12(1):301. PMID: 21241526; PMCID: PMC3091296.
    42. Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz D, Sali A. Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains. Protein Sci. 2010 Nov; 19(11):2110-21. PMID: 20799350; PMCID: PMC3005782.
    43. Ho RH, Leake BF, Kilkenny DM, Meyer Zu Schwabedissen HE, Glaeser H, Kroetz D, Kim RB. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics. 2010 Jan; 20(1):45-57. PMID: 20010382; PMCID: PMC2883163.
    44. Kroetz D, Yee SW, Giacomini KM. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther. 2010 Jan; 87(1):109-16. PMID: 19940846; PMCID: PMC2923224.
    45. Kroetz D, Ahituv N, Burchard EG, Guo S, Sali A, Giacomini KM. Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. Pharmacogenomics. 2009 Oct; 10(10):1569-76. PMID: 19842929; PMCID: PMC2923222.
    46. Kelly L, Pieper U, Eswar N, Hays FA, Li M, Roe-Zurz Z, Kroetz D, Giacomini KM, Stroud RM, Sali A. A survey of integral alpha-helical membrane proteins. J Struct Funct Genomics. 2009 Dec; 10(4):269-80. PMID: 19760129.
      View in: PubMed
    47. Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, Gow JM, Ha C, Ma B, Poon A, Johns SJ, Stryke D, Castro RA, Tahara H, Choi JH, Chen L, Picard N, Sjödin E, Roelofs MJ, Ferrin TE, Myers R, Kroetz D, Kwok PY, Giacomini KM. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One. 2009 Sep 09; 4(9):e6942. PMID: 19742321; PMCID: PMC2735003.
    48. Innocenti F, Kroetz D, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14. PMID: 19349540; PMCID: PMC2690389.
    49. Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, Bainton RJ. Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Neurosci. 2009 Mar 18; 29(11):3538-50. PMID: 19295159; PMCID: PMC3040577.
    50. Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz D. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One. 2008; 3(12):e3981. PMID: 19096711; PMCID: PMC2602850.
    51. Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz D. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther. 2008 Dec; 327(3):707-15. PMID: 18815352; PMCID: PMC2761654.
    52. Tutka P, Dempsey DA, Jacob P, Benowitz NL, Kroetz D. Nicotine metabolism in pregnant and nonpregnant rabbits. Nicotine Tob Res. 2008 Aug; 10(8):1385-90. PMID: 18686186; PMCID: PMC2923225.
    53. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz D. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008 Jun; 325(3):859-68. PMID: 18364470; PMCID: PMC2612728.
    54. Gow JM, Hodges LM, Chinn LW, Kroetz D. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008 May; 325(2):435-42. PMID: 18287207; PMCID: PMC2612726.
    55. Gow JM, Chinn LW, Kroetz D. The effects of ABCB1 3'-untranslated region variants on mRNA stability. Drug Metab Dispos. 2008 Jan; 36(1):10-5. PMID: 17940136.
      View in: PubMed
    56. Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz D. Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother. 2007 Jul; 60(1):61-7. PMID: 17510066.
      View in: PubMed
    57. Bangsberg DR, Kroetz D, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May; 4(2):65-72. PMID: 17547827.
      View in: PubMed
    58. Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz D. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos. 2007 Jul; 35(7):1126-34. PMID: 17431031.
      View in: PubMed
    59. Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, Kroetz D, Goldstein DB, Sisodiya SM. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia. 2007 Apr; 48(4):674-83. PMID: 17437410.
      View in: PubMed
    60. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz D. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug; 82(2):197-203. PMID: 17361129.
      View in: PubMed
    61. Jeong H, Herskowitz I, Kroetz D, Rine J. Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet. 2007 Mar 09; 3(3):e39. PMID: 17352537; PMCID: PMC1817653.
    62. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz D, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45. PMID: 17339863; PMCID: PMC5006950.
    63. Chinn LW, Kroetz D. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther. 2007 Feb; 81(2):265-9. PMID: 17259950.
      View in: PubMed
    64. de Jong FA, Scott-Horton TJ, Kroetz D, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007 Jan; 81(1):42-9. PMID: 17185998.
      View in: PubMed
    65. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz D. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol. 2006 Nov; 26(11):2462-8. PMID: 16917105; PMCID: PMC1904341.
    66. Kroetz D. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006 Sep 10; 24(26):4225-7. PMID: 16895999.
      View in: PubMed
    67. Xu F, Ng VY, Kroetz D, de Montellano PR. CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease. J Pharmacol Exp Ther. 2006 Aug; 318(2):835-9. PMID: 16707724.
      View in: PubMed
    68. Komoto C, Nakamura T, Sakaeda T, Kroetz D, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006 Apr; 21(2):126-32. PMID: 16702732.
      View in: PubMed
    69. Badagnani I, Sorani M, Edwards RH, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson EJ, Taylor T, Chan W, De La Cruz M, Ferrin TE, Burchard EG, Herskowitz I, Kroetz D, Giacomini KM. PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network. Pharmacol Rev. 2006 Mar; 58(1):5-6. PMID: 16507879.
      View in: PubMed
    70. Nguyen TD, Gow JM, Chinn LW, Kelly L, Jeong H, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson E, Taylor T, Ferrin TE, Sali A, Giacomini KM, Kroetz D. PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network. Pharmacol Rev. 2006 Mar; 58(1):1-2. PMID: 16507877.
      View in: PubMed
    71. Shu Y, Urban TJ, Leabman MK, Fujita T, Erdman AR, Lagpacan LL, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Taylor TR, Chan W, De La Cruz M, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Herskowitz I, Kroetz D, Giacomini KM. PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev. 2006 Mar; 58(1):3-4. PMID: 16507878.
      View in: PubMed
    72. Yu Z, Ng VY, Su P, Engler MM, Engler MB, Huang Y, Lin E, Kroetz D. Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid. J Pharmacol Exp Ther. 2006 May; 317(2):732-8. PMID: 16421287.
      View in: PubMed
    73. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz D, Milos PM, Ratain MJ, Thummel K. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec; 78(6):559-81. PMID: 16338273.
      View in: PubMed
    74. Wang D, Johnson AD, Papp AC, Kroetz D, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005 Oct; 15(10):693-704. PMID: 16141795.
      View in: PubMed
    75. Seubert JM, Xu F, Graves JP, Collins JB, Sieber SO, Paules RS, Kroetz D, Zeldin DC. Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2005 Sep; 289(3):F552-61. PMID: 15798089.
      View in: PubMed
    76. Kroetz D, Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol. 2005; 45:413-38. PMID: 15822183.
      View in: PubMed
    77. Pauli-Magnus C, Kroetz D. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res. 2004 Jun; 21(6):904-13. PMID: 15212152.
      View in: PubMed
    78. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz D, Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol. 2004 Apr; 286(4):F720-6. PMID: 14665429.
      View in: PubMed
    79. Xu F, Falck JR, Ortiz de Montellano PR, Kroetz D. Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther. 2004 Mar; 308(3):887-95. PMID: 14634044.
      View in: PubMed
    80. Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz D. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther. 2003 Nov; 74(5):487-98. PMID: 14586389.
      View in: PubMed
    81. Kroetz D, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003 Aug; 13(8):481-94. PMID: 12893986.
      View in: PubMed
    82. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, Kroetz D, Ferrin TE, Clark AG, Risch N, Herskowitz I, Giacomini KM. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A. 2003 May 13; 100(10):5896-901. PMID: 12719533; PMCID: PMC156298.
    83. Pauli-Magnus C, Kroetz D. MDR1 reference sequence and reference function. Clin Pharmacol Ther. 2002 Jul; 72(1):100-1. PMID: 12152008.
      View in: PubMed
    84. Kroetz D, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol. 2002 Jun; 13(3):273-83. PMID: 12045397.
      View in: PubMed
    85. LeBrun LA, Xu F, Kroetz D, Ortiz de Montellano PR. Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family. Biochemistry. 2002 May 07; 41(18):5931-7. PMID: 11980497.
      View in: PubMed
    86. Ring HZ, Kroetz D. Candidate gene approach for pharmacogenetic studies. Pharmacogenomics. 2002 Jan; 3(1):47-56. PMID: 11966402.
      View in: PubMed
    87. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz D. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000 Nov 24; 87(11):992-8. PMID: 11090543.
      View in: PubMed
    88. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz D. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol. 2000 May; 57(5):1011-20. PMID: 10779386.
      View in: PubMed
    89. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz D, Giacomini KM. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar; 28(3):329-34. PMID: 10681378.
      View in: PubMed
    90. Spiegelstein O, Kroetz D, Levy RH, Yagen B, Hurst SI, Levi M, Haj-Yehia A, Bialer M. Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. Pharm Res. 2000 Feb; 17(2):216-21. PMID: 10751038.
      View in: PubMed
    91. Hoch U, Zhang Z, Kroetz D, Ortiz de Montellano PR. Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases. Arch Biochem Biophys. 2000 Jan 01; 373(1):63-71. PMID: 10620324.
      View in: PubMed
    92. Engler MM, Engler MB, Kroetz D, Boswell KD, Neeley E, Krassner SM. The effects of a diet rich in docosahexaenoic acid on organ and vascular fatty acid composition in spontaneously hypertensive rats. Prostaglandins Leukot Essent Fatty Acids. 1999 Nov; 61(5):289-95. PMID: 10670690.
      View in: PubMed
    93. Engler MM, Engler MB, Goodfriend TL, Ball DL, Yu Z, Su P, Kroetz D. Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Proc Soc Exp Biol Med. 1999 May; 221(1):32-8. PMID: 10320629.
      View in: PubMed
    94. Kroetz D, Yook P, Costet P, Bianchi P, Pineau T. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem. 1998 Nov 20; 273(47):31581-9. PMID: 9813074.
      View in: PubMed
    95. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz D, Szklarz G, Harlow G, Halpert JR, Correia MA. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry. 1998 Sep 08; 37(36):12536-45. PMID: 9730826.
      View in: PubMed
    96. Su P, Kaushal KM, Kroetz D. Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol. 1998 Aug; 275(2 Pt 2):R426-38. PMID: 9688677.
      View in: PubMed
    97. Kroetz D, Huse LM, Thuresson A, Grillo MP. Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol. 1997 Sep; 52(3):362-72. PMID: 9281597.
      View in: PubMed
    98. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz D, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995 Jun; 15(6):3012-22. PMID: 7539101; PMCID: PMC230532.
    99. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz D, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994 Jun 01; 47(11):1969-79. PMID: 8010982.
      View in: PubMed
    100. Kroetz D, McBride OW, Gonzalez FJ. Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry. 1993 Nov 02; 32(43):11606-17. PMID: 8218228.
      View in: PubMed
    101. Kroetz D, Loiseau P, Guyot M, Levy RH. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther. 1993 Nov; 54(5):485-97. PMID: 8222491.
      View in: PubMed
    102. Pisani F, Haj-Yehia A, Fazio A, Artesi C, Oteri G, Perucca E, Kroetz D, Levy RH, Bialer M. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia. 1993 Sep-Oct; 34(5):954-9. PMID: 8104783.
      View in: PubMed
    103. Kroetz D, Kerr BM, McFarland LV, Loiseau P, Wilensky AJ, Levy RH. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther. 1993 Mar; 53(3):306-15. PMID: 8453849.
      View in: PubMed
    Back to TOP